Drug intelligence / Profile preview

Tiaopi Anchang

Development stage: Unknown
Lead developer: China-Japan Friendship Hospital
Administration: Oral

Overview

Tiaopi Anchang is a Traditional Chinese Medicine (TCM) herbal prescription developed by the China-Japan Friendship Hospital. It is specifically formulated based on the 'Spleen-Kidney Deficiency' pathogenesis theory to treat patients with metastatic colorectal cancer. In clinical trial settings, it is evaluated as an integrated treatment alongside standard Western chemotherapy. The primary goals of the therapy are to increase the chemotherapy completion rate, reduce treatment-related toxicities, and improve TCM syndrome scores, which reflect the patient's overall quality of life and symptom burden.

Other names: Tiaopi Anchang prescriptionTiaopi Anchang formula

Targets

MMP3 (Matrix metalloproteinase-3)

Beyond the preview

Go deeper on Tiaopi Anchang.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Tiaopi Anchang.

Explore the full profile